KRAS and non-small cell lung carcinoma: Therefore, the main objective of this clinical study was to increase insight in the correlation between selected molecular biomarkers in genes coding for VEGF-A, VEGF receptors 1 and 2 (VEGF-R1 and VEGFR-2), and KRAS, circulating levels of angiogenic mediators and expression of endothelial markers, and the clinical response to the combined treatment of carboplatin, paclitaxel, and bevacizumab in advanced NSCLC patients.